 |
 |
 |
|
|
| |
|
| |
 |
 Laboratorios
Calier, one of the companies which forms the Indukern
Group, is dedicated to the research, development and marketing
of veterinary products, counting on a wide international projection.
Founded in 1969, a progressive and continuous growth has elevated
the laboratory to a leading position in the ranking of a sector
in Spain integrated by 28 companies which participate and compete
with all the multinational companies.
Laboratorios
Calier orients its activities towards the research, the development
and the marketing of products for veterinary use destined to
breeding and domestic animals.
In consequence, the production lines extend from the oral forms,
with their different options, to the injectable forms.
Antibacterials, antiparasitics, vaccines, hormonal activity
regulators, vitamins, nutritional products, immunotherapics,
anti-inflammatory drugs, cosmetics, etc. form part of the therapeutic
tools that Calier puts at the disposal of the veterinarian for
the care, the health and the welfare of the animal. At the present
moment the catalogue contains over 100
products, elaborated by following the GMP standards..
The dedication to be widely present in the market has led Laboratorios
Calier to be currently present in more than 70 countries of
the five continents, either through the 9
existing subsidiaries, or through its distributor network.
.
The effort displayed by Calier in the areas of manufacture,
development and innovation has allowed the consolidation of
an important R&D department. Here 25 technicians carry out
an exciting job, sometimes in close collaboration with the 20
Public Research Centres, with which signed agreements exist
for the development of new specialities.
This company policy and the excellent results obtained in R&D
have deserved an important governmental recognition: Laboratorios
Calier was awarded the "Technological Innovation Prize"
in the 1999 edition.
At the present time, applications of biotechnology in Animal
Health constitute Calier’s main bet at the moment of defining
its company development strategies, dedicating a large part
of its resources to innovation in this field.
 |
|
|
